US › Healthcare

ARS Pharmaceuticals, Inc (SPRY)

US · Healthcare · Biotechnology

$5.32-2.56%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$22.7M
Revenue YoY
+184.5%
Net profit
$-60.6M
Profit YoY
-78.6%
EPS
$-0.61
EPS estimate
$-0.53
Net margin
-267.3%

EPS came in at -0.61 against a street estimate of -0.53 — a miss of 15.1%.

Key statistics

Market cap
$542.2M
Forward P/E
0.0
P/B
8.28
Book value
$0.62
EPS (TTM)
$-2.00
52-week high
$18.00
52-week low
$4.91
50-day MA
$8.14
200-day MA
$8.99
Beta
0.97

Analyst view

Analysts rate ARS Pharmaceuticals, Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $26.75.

Shareholding

Insiders
16.21%
Institutions
94.65%

Largest institutional holders

FundStake
RA Capital Management, LLC10.94%
Orbimed Advisors, LLC8.35%
Rubric Capital Management LP8.06%
Deerfield Management Co7.56%
Millennium Management LLC6.03%
BlackRock Inc5.05%
Aberdeen Group PLC4.14%
SR ONE CAPITAL MANAGEMENT, LP4.04%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for ARS Pharmaceuticals, Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.